1/n Excited to share the first, first author paper of my postdoc! Targeting of ACSS2 with a transition state mimetic to inhibit triple negative breast cancer growth. A thread. @Schuglab@TheWistar#ACSS2#Acetate#Metabolism#CancerResearch
https://t.co/al6gMPLqFY
My last day in person @SchugLab. After over 4 years in #cancer#metabolism I will be moving to an industry position. Thanks for everything Zach!! Also Zach is hiring for a postdoc, reach out if you need any details and want to join an awesome group! #Acss2#postdoc#postdocjobs
🔬𝐘𝐨𝐮𝐫 𝐃𝐨𝐧𝐚𝐭𝐢𝐨𝐧𝐬 𝐚𝐭 𝐖𝐨𝐫𝐤🧬
Meet 2021 PBCC Research Grant Winner Dr. Zachary Schug of @TheWistar!
Dr. Schug has identified a nutrient that feeds cancer cells & causes them to metastasize. He hopes to study that process & develop therapies for #breastcancer👇
It's important to share factual info when it comes to the #COVID19 vaccine. Fox Chase's @GlennRallPhD and @templemedschool's Dr. Heather Clauss (@heathercmd2) share answers to some common questions about the #COVIDvaccine. Watch here: https://t.co/X7V8Ld61CN.
7/7 Short answer, ACSS1 can use either acetate or propionate, ACSS2 heavily favors acetate, and ACSS3 heavily favors propionate. Lastly, the ACSS2 inhibitors we tested were highly specific for ACSS2 over ACSS1 or ACSS3. Looking forward to pursuing our findings further!!
1/n Excited to share the first, first author paper of my postdoc! Targeting of ACSS2 with a transition state mimetic to inhibit triple negative breast cancer growth. A thread. @Schuglab@TheWistar#ACSS2#Acetate#Metabolism#CancerResearch
https://t.co/al6gMPLqFY
6/n We also tested the ability of the other short chain acyl-CoA synthetase family members ACSS1 and ACSS3 to catalyze the conversion of acetate and propionate to their acyl-CoA products.